Vaxil Bio Ltd. VXLLF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 60.92% | -- | -- | -- | 162.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.09% | -- | -- | -- | 55.89% |
| Operating Income | -57.09% | -- | -- | -- | -55.89% |
| Income Before Tax | 644.72% | -- | -- | -- | 34.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 644.72% | -- | -- | -- | 34.83% |
| Earnings from Discontinued Operations | 110.53% | -- | -- | -- | -309.80% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 486.00% | -- | -- | -- | 13.15% |
| EBIT | -57.09% | -- | -- | -- | -55.89% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 470.59% | -- | -- | -- | 13.27% |
| Normalized Basic EPS | -162.50% | -- | -- | -- | 34.88% |
| EPS Diluted | 470.59% | -- | -- | -- | 13.27% |
| Normalized Diluted EPS | -162.50% | -- | -- | -- | 34.88% |
| Average Basic Shares Outstanding | 26.20% | -- | -- | -- | 0.00% |
| Average Diluted Shares Outstanding | 26.20% | -- | -- | -- | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |